TLSI, TLSIW · CIK 0001826667 · operating
TriSalus Life Sciences develops drug delivery technology and immuno-oncology therapeutics focused on difficult-to-treat liver and pancreatic cancers. The company's primary product is its Pressure Enabled Drug Delivery (PEDD) infusion system platform, which includes the TriNav infusion system used in transarterial radioembolization and chemoembolization procedures for hepatic malignancies and metastases. The company is also advancing the Pancreatic Retrograde Venous Infusion device, currently in Phase 1 clinical trials for locally advanced pancreatic cancer treatment.
Beyond its device portfolio, TriSalus is developing nelitolimod, an investigational immunotherapeutic in Phase 1 trials for multiple indications including uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. The company markets its offerings to interventional radiologists, IR technicians, medical oncologists, and nursing staff through direct sales representatives and managers.
Headquartered in Westminster, Colorado, TriSalus operates with approximately 110 full-time employees. The company was incorporated in Delaware and is listed on Nasdaq. Founded in 2009, TriSalus operates within the surgical and medical instruments sector, with its clinical-stage pipeline and device commercialization efforts primarily directed toward the U.S. market.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.31 | $-1.31 | +80.5% | |
| 2023 | $-6.73 | $-6.73 | — | |
| 2022 | — | — | — | |
| 2021 | — | — | — |